News Ipsen to buy rare disease firm Clementia for up to $1.31bn France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
News Novartis raises forecasts for three key growth products Novartis raises sales expectations for three growth products – Kesimpta, Scemblix, and Leqvio – by $4bn as it sets a 5% midterm revenue growth target.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.